ArticleProstate cancer and prostatic diseases2020
Financial implications of biparametric prostate MRI.
Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- A preoperative magnetic resonance imaging-based model to predict biochemical failure after radical prostatectomy.Scientific reports · 2023Trial
- Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.BMJ open · 2022Trial
- Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.Scientific reports · 2021Trial
- The Role of Micro-Ultrasound in Prostate Cancer Detection.Current urology reports · 2026Review
- Does gadolinium truly enhance the active surveillance of men with prostate cancer?BJUI compass · 2026Article
- Implementation of a biparametric prostate MRI protocol with a recall system for intravenous contrast: an analysis of recall rates and comparison of PI-RADS category distribution.Abdominal radiology (New York) · 2026Article
- Apparent diffusion coefficient values in prostate cancer: Association with pathological grade groups and correlation with Ki-67 proliferation index.Journal of clinical imaging science · 2026Article
- Diagnostic accuracy of biparametric vs. multiparametric MRI for clinically significant prostate cancer.World journal of urology · 2025Article
- On-table monitoring of prostate MRI could enable tailored utilisation of gadolinium contrast.European radiology · 2025Observational
- Ultra-fast biparametric MRI in prostate cancer assessment: Diagnostic performance and image quality compared to conventional multiparametric MRI.European journal of radiology open · 2025Article
- Article
- Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer.European urology open science · 2025Article
- Biparametric MRI in prostate cancer during active surveillance: is it safe?European radiology · 2024Review
- Utility of dynamic contrast enhancement for clinically significant prostate cancer detection.BJUI compass · 2024Article
- Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.Annals of internal medicine · 2024Article
- Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging.American journal of cancer research · 2024Article
- Relationship between Eccentricity and Volume Determined by Spectral Algorithms Applied to Spatially Registered Bi-Parametric MRI and Prostate Tumor Aggressiveness: A Pilot Study.Diagnostics (Basel, Switzerland) · 2023Article
- Comparison of Biparametric and Multiparametric Prostate Magnetic Resonance Imaging in Predicting Oncologic Outcomes After Radical Prostatectomy.Medeniyet medical journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiparametric magnetic resonance imaging (MP-MRI) targeted biopsy has been shown to identify more clinically-significant cancers and reduce the detection of clinically-insignificant disease when compared to systematic biopsy; however, the wide-spread accessibility of MP-MRI is limited. A potential strategy for reducing the cost, study time, and contrast-associated risks associated with MP-MRI is elimination of the dynamic contrast-enhanced (DCE) sequence, relying instead on biparametric MRI (BP-MRI). BP-MRI has been shown to have a diagnostic accuracy and cancer detection rate that are equivalent to those of MP-MRI.
methodsWe modeled the potential cost of BP-MRI compared to MP-MRI to determine what cost savings would occur if DCE was eliminated from these studies.
resultsWhen controlled for a 45 min time window that allows for one full MP-MRI or three full BP-MRI studies, the BP-MRI 45 min gross profit is $1531.32. This is an increase in gross profit of $892.58 for the 45 min time window or $10,710.98 in a 9-h business day when performing BP-MRI compared to MP-MRI for prostate cancer detection.
conclusionsBP-MRI has the potential to result in substantial cost benefit and increased access to MRI in the diagnostic workflow and risk-stratification of men being evaluated for prostate cancer when compared to conventional MP-MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.